ST045849
Based on 1 Customer Validation
ST045849 (OGT-IN-2) is a small-molecule OGT inhibitor with an IC50 of 30 μM against sOGT and 53 μM against ncOGT. ST045849 is applicable to research on metabolism-related diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.2%
- CAS No.: 442665-87-4
- Formule: C23H27ClN2O3S
- Masse moléculaire:446.99
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
Lipid Metabolism Compound Library
HY-L091
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Activité biologique
IC50: 30 ± 2 μM (sOGT), 53 ± 7 μM (ncOGT)[1]
OGT-IN-2 (Compound 4) exhibits IC50 values of 30 μM and 53 μM against sOGT and ncOGT, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 442665-87-4
-
Appearance Solid
-
Masse moléculaire 446.99
-
Formule C23H27ClN2O3S
-
Color White to off-white
-
SMILES
O=C(C1)N(/C(SC1C(O)=O)=N/C(C=C2)=CC=C2Cl)CCC3(C[C@H](C4)C5)C[C@H]5C[C@H]4C3
-
Synonyms
OGT-IN-2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 125 mg/mL (279.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (4.65 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Bricelj A, et al. OSMI-4-based PROTACs do not influence O-GlcNAc transferase and O-GlcNAcylation levels in cells. RSC Adv. 2025;15(31):25717-25723. Published 2025 Jul 18. [Content Brief]
[2]. Gross BJ, et al. Discovery of O-GlcNAc transferase inhibitors. J Am Chem Soc. 2005 Oct 26;127(42):14588-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2372 mL | 11.1859 mL | 22.3719 mL | 55.9297 mL |
| 5 mM | 0.4474 mL | 2.2372 mL | 4.4744 mL | 11.1859 mL | |
| 10 mM | 0.2237 mL | 1.1186 mL | 2.2372 mL | 5.5930 mL | |
| 15 mM | 0.1491 mL | 0.7457 mL | 1.4915 mL | 3.7286 mL | |
| 20 mM | 0.1119 mL | 0.5593 mL | 1.1186 mL | 2.7965 mL | |
| 25 mM | 0.0895 mL | 0.4474 mL | 0.8949 mL | 2.2372 mL | |
| 30 mM | 0.0746 mL | 0.3729 mL | 0.7457 mL | 1.8643 mL | |
| 40 mM | 0.0559 mL | 0.2796 mL | 0.5593 mL | 1.3982 mL | |
| 50 mM | 0.0447 mL | 0.2237 mL | 0.4474 mL | 1.1186 mL | |
| 60 mM | 0.0373 mL | 0.1864 mL | 0.3729 mL | 0.9322 mL | |
| 80 mM | 0.0280 mL | 0.1398 mL | 0.2796 mL | 0.6991 mL | |
| 100 mM | 0.0224 mL | 0.1119 mL | 0.2237 mL | 0.5593 mL |
ST045849 Related Classifications
HY-136282 Related Classifications
Powered by Bioz